Showing 49 results
March 2021
-
Media Release
Novartis receives approval for Kymriah® (tisagenlecleucel) by Health Sciences Authority as Singapore’s first commercially approved CAR-T therapy
Kymriah, the first chimeric antigen receptor T-cell (CAR-T) therapy approved in Singapore, is indicated as a one-time treatment manufactured individually for each patient. Novartis works closely… -
Media Release
Novartis Piqray® - First and only treatment specially for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer receives HSA approval
Piqray (alpelisib) is the only treatment approved specifically to address PIK3CA mutation The approval was based on SOLAR-1 Phase III trial showing Piqray plus fulvestrant nearly doubled median…
May 2020
-
In The News
Leading without being "the boss": Novartis SG's Kevin Zou
-
Media Release
Novartis Singapore returns Job Support Scheme payout worth SGD3.7 Million; aids community efforts against COVID-19
Novartis Singapore commits to no retrenchments due to the COVID-19 pandemic, returns SGD 3.7 million worth of Job Support Scheme (JSS) in April 2020 and declines any future payouts related to the… -
Featured News
Supporting our community during this pandemic
-
In The News
新加坡区总裁邹澄：诺华集团要推动本地药剂生产数码化 提升运营效率
